L&C Bio (CEOHwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, “MegaDerm Plus.” This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales […]
Company's Connected Platform on Full Display in Booth 1426 at the 2025 NADA Show This Month Cars.com Inc. (NYSE: CARS) (d/b/a “Cars Commerce”), an audience-driven technology company empowering automotive, shares new data about the value of its connected platform. Dealer customers taking advantage of more than one of the platform's four core capabilities (Marketplace, Digital
(NASDAQ:ICU), DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Mayo Clinic is now cleared to enroll subjects in the company's NEUTRALIZE-AKI pivotal trial, increasing the number of activated sites to 15.
(TSX-V:RKV), VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI infrastructure by OpenAI, SoftBank, and Oracle through their joint venture, Stargate. This historic initiative marks a defining
(NasdaqGM:FCEL), DANBURY, Conn., Jan. 22, 2025 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL), a Connecticut-based global leader in delivering clean, innovative fuel cell solutions for the supply, recovery, and storage of energy, announced that it will build a 7.4 MW fuel cell power plant in Hartford, Conn. The project will deliver Class 1 renewable
(NASDAQ:ELTX), Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival (“DFS”) expected in H1 2025; positive results could support rapid advancement into Phase 3 development
(NASDAQ:STRM), ATLANTA, Jan. 22, 2025 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of RevID with a 120-bed, Oracle Health-EHR based health system with facilities in Kentucky. Closed in partnership
(NYSE:UCB),(NYSE:UCB-PI), GREENVILLE, S.C., Jan. 22, 2025 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (United) today announced net income for the fourth quarter of 2024 of $75.8 million and pre-tax, pre-provision income of $108 million. Diluted earnings per share of $0.61 for the quarter represented an increase of $0.50 from the fourth quarter a
(NasdaqGM:NTLA), CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a wholly owned investigational
(NYSE:COHR), PITTSBURGH, Jan. 22, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in laser and photonic solutions, today announces the launch of new pin-hole array biochips for medical diagnostics, with a focus on gene sequencing applications. Developed by the Coherent advanced optics team, this groundbreaking approach consolidates the entire production process, addressing